HRP20241740T1 - Liječenje raka prostate - Google Patents
Liječenje raka prostate Download PDFInfo
- Publication number
- HRP20241740T1 HRP20241740T1 HRP20241740TT HRP20241740T HRP20241740T1 HR P20241740 T1 HRP20241740 T1 HR P20241740T1 HR P20241740T T HRP20241740T T HR P20241740TT HR P20241740 T HRP20241740 T HR P20241740T HR P20241740 T1 HRP20241740 T1 HR P20241740T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- subject
- use according
- administering
- oral
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 17
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 229960003604 testosterone Drugs 0.000 claims 6
- 238000012423 maintenance Methods 0.000 claims 4
- 239000003163 gonadal steroid hormone Substances 0.000 claims 2
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 claims 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| EP17823017.3A EP3518932B1 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
| PCT/EP2017/074849 WO2018060463A2 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241740T1 true HRP20241740T1 (hr) | 2025-02-28 |
Family
ID=60915459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241740TT HRP20241740T1 (hr) | 2016-09-30 | 2017-09-29 | Liječenje raka prostate |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US10449191B2 (https=) |
| EP (2) | EP3518932B1 (https=) |
| JP (1) | JP7062673B2 (https=) |
| CN (1) | CN110248661A (https=) |
| AU (2) | AU2017334035B2 (https=) |
| BR (1) | BR112019006228A2 (https=) |
| CA (1) | CA3038875A1 (https=) |
| DK (1) | DK3518932T3 (https=) |
| ES (1) | ES3002857T3 (https=) |
| FI (1) | FI3518932T3 (https=) |
| HR (1) | HRP20241740T1 (https=) |
| HU (1) | HUE070578T2 (https=) |
| IL (3) | IL300071A (https=) |
| LT (1) | LT3518932T (https=) |
| MA (1) | MA46361A (https=) |
| MX (2) | MX2019003733A (https=) |
| NZ (1) | NZ752918A (https=) |
| PL (1) | PL3518932T3 (https=) |
| PT (1) | PT3518932T (https=) |
| SI (1) | SI3518932T1 (https=) |
| WO (1) | WO2018060463A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| WO2021069700A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| US20230384316A1 (en) * | 2020-10-20 | 2023-11-30 | Baylor College Of Medicine | Multiplex metabolic markers in plasma for early detection of african american prostate cancer |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| JP2024540922A (ja) | 2021-10-18 | 2024-11-06 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
| WO2023152611A1 (en) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| US6297379B1 (en) | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6849738B2 (en) | 2000-02-29 | 2005-02-01 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| US20050043315A1 (en) | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| KR20100090726A (ko) | 2002-02-26 | 2010-08-16 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
| US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| CN100424078C (zh) | 2003-07-07 | 2008-10-08 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
| ES2494842T3 (es) | 2005-07-22 | 2014-09-16 | Takeda Pharmaceutical Company Limited | Agente que previene la ovulación precoz |
| PE20090044A1 (es) | 2007-04-06 | 2009-01-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| EP3185881B1 (en) | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| AU2016317955B2 (en) | 2015-09-01 | 2021-05-20 | Abbvie Inc. | Methods of administering Elagolix |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
-
2017
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/en not_active Ceased
- 2017-09-29 ES ES17823017T patent/ES3002857T3/es active Active
- 2017-09-29 CA CA3038875A patent/CA3038875A1/en active Pending
- 2017-09-29 PT PT178230173T patent/PT3518932T/pt unknown
- 2017-09-29 FI FIEP17823017.3T patent/FI3518932T3/fi active
- 2017-09-29 EP EP17823017.3A patent/EP3518932B1/en active Active
- 2017-09-29 HR HRP20241740TT patent/HRP20241740T1/hr unknown
- 2017-09-29 LT LTEPPCT/EP2017/074849T patent/LT3518932T/lt unknown
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 EP EP24212224.0A patent/EP4520398A3/en active Pending
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 HU HUE17823017A patent/HUE070578T2/hu unknown
- 2017-09-29 PL PL17823017.3T patent/PL3518932T3/pl unknown
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 SI SI201731574T patent/SI3518932T1/sl unknown
- 2017-09-29 DK DK17823017.3T patent/DK3518932T3/da active
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt not_active Application Discontinuation
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US12097198B2/en active Active
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047B2/en active Active
-
2024
- 2024-06-28 US US18/758,904 patent/US12144809B1/en active Active
- 2024-11-05 US US18/937,891 patent/US12336990B2/en active Active
- 2024-11-25 US US18/959,460 patent/US20250082632A1/en active Pending
-
2025
- 2025-07-09 US US19/264,673 patent/US20250332166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241740T1 (hr) | Liječenje raka prostate | |
| JP2019529574A5 (https=) | ||
| US20110124617A1 (en) | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent | |
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| JP2013501731A5 (https=) | ||
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| HUP0000261A2 (hu) | Módszer prosztatatúltengés és prosztatarák kezelésére | |
| JP2016509050A5 (https=) | ||
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| RU2015119223A (ru) | Система дозированного распределения | |
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| JP2019507786A5 (https=) | ||
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| CN105209044B (zh) | 用于疼痛病症的治疗性米氮平组合物 | |
| KR20070085470A (ko) | 핫플러쉬 치료용 ｓ-미르타자핀 | |
| JP2019535830A5 (https=) | ||
| WO2007139433A8 (en) | Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| Santiago et al. | Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. | |
| JP6567971B2 (ja) | 女性性機能障害の治療におけるブレメラノチドの使用 | |
| RU2325160C1 (ru) | Средство для лечения рака предстательной железы и профилактики его рецидива | |
| Dolcet | Advancing and Historical Reversible Contraceptive Solutions for Feline Reproductive Control | |
| Sehgal et al. | Erectile Dysfunction/Impotence: An update of Drugs, Drug Delivery/Management, and Approaches or strategies | |
| Liao et al. | Adrenomedullin inhibits norepinephrine-induced contraction of rat seminal vesicle |